PCM
MREO

Prelude Capital Management’s Mereo BioPharma MREO Stock Holding History

Prelude Capital Management’s Portfolio MREO Stock Details MREO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-52,521
Closed -$188K – 1722
2020
Q4 		$188K Buy
+52,521
New +$132K ﹤0.01% 1129

Other funds holding MREO

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Prelude Capital Management's MREO Position: Q1 2021 in Review

Prelude Capital Management sold out of Mereo BioPharma (MREO) in Q1 2021, closing a stake of 52,521 shares — an estimated $188K sold.

Prelude Capital Management first reported a position in MREO in Q4 2020 and held it in 1 quarter. The position peaked at $188K in Q4 2020. 66 funds tracked by Wall St. Rank hold MREO as of Q1 2021.

  • Prelude Capital Management reported no remaining Mereo BioPharma position as of Q1 2021 after selling out during the quarter.
  • Prelude Capital Management sold 52,521 Mereo BioPharma shares in Q1 2021, an estimated $188K.
  • Prelude Capital Management first reported a position in Mereo BioPharma in Q4 2020 and held it in 1 quarter.
  • Prelude Capital Management's Mereo BioPharma position peaked at $188K in Q4 2020.
  • 66 funds tracked by Wall St. Rank held Mereo BioPharma as of Q1 2021.

Based on Prelude Capital Management's 13F filing for Q1 2021, filed 17 May 2021.